Product Description
The Chinese dental bone graft substitutes and other biomaterials market was valued at nearly $264 million in 2024. This is expected to increase over the forecast period at a CAGR of 14.7% to reach nearly $690 million.
The full report suite on the Chinese market for dental bone graft substitutes (DBGSs) and other biomaterials includes DBGSs, dental barrier membranes, local antimicrobial periodontal treatments and dental soft tissue wound care. Collectively, these segments will be referred to as the dental biomaterials market.
MARKET REPORT DATA TYPES INCLUDED
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Procedure Numbers
- Market Drivers & Limiters
- Market Forecasts Until 2031, and Historical Data to 2024
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
CHINESE DENTAL BONE GRAFT SUBSTITUTES MARKET TRENDS
The total market for dental biomaterial products in China will be driven by the growing number of dental implants being placed. China is widely regarded as the next major growth market for dental implants, largely due to the implementation of volume-based procurement (VBP), which is expected to make implant procedures more affordable for the general population. This initiative will lead to a surge in dental implant procedures across mainland China, procedures that are closely linked to the unit sales of DBGSs and dental barrier membranes. Additionally, the bundling of implant products with biomaterials will further support the expansion of the DBGS and dental biomaterials market.
CHINA DENTAL BONE GRAFT SUBSTITUTES MARKET SHARE INSIGHTS
- Geistlich, a globally recognized leader in regenerative materials, dominated the expanding xenograft market in China in 2024. The company’s strong reputation and trusted global presence have played a pivotal role in driving the adoption and growth of xenograft materials in the region. By establishing a local affiliate in China, Geistlich has effectively addressed cultural barriers and strengthened brand awareness among clinicians. Despite rising competition from domestic manufacturers, Geistlich is expected to maintain its leading position in the Chinese market over the forecast period.
- Shanxi OsteoRad is one of the few allograft providers to gain CFDA approval for its products. Due to the regulatory nature of allograft materials in China, competition is highly limited. Many global leaders for allograft products have not been able to enter the market, solidifying Shanxi OsteoRad’s position. It held the second-leading position in the overall DBGS and biomaterials market in China in 2024.
- Dexcel Pharma placed third in the overall DBGS and other biomaterials market in 2024. The company was the overwhelming leader in the local antimicrobial periodontal treatment market throughout Asia Pacific. Founded in 1968, Dexcel Pharma is Israel’s largest private pharmaceutical company. It offers PerioChip®, which comes in the form of a small biodegradable chip that can be placed manually into a periodontal pocket. Each chip contains 2.5 mg of chlorohexidine digluconate, an antiseptic agent. Dexcel’s PerioChip® is widely regarded as an exceptional treatment option for periodontal pockets, which is why it has seen international success for over two decades.
MARKET SEGMENTATION SUMMARY
- Dental Bone Graft Substitute (DBGS) – Further Segmented Into:
- Type: Allografts, Xenografts, Synthetics.
- Dental Barrier Membranes – Further Segmented Into:
- Material: Allografts, Xenografts, Synthetics.
- Type: Resorbable, Non-Resorbable
- Antimicrobial Periodontal Treatment
- Dental Soft Tissue Wound Care – Further Segmented Into:
- Type: Plug, Tape, Foam
*Segment is analyzed at a unit level only.
RESEARCH SCOPE SUMMARY
| Report Attribute | Details |
|---|---|
| Region | China |
| Base Year | 2024 |
| Forecast | 2025-2031 |
| Historical Data | 2021-2024 |
| Quantitative Coverage | Procedure Numbers, Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Coverage | Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
CONTACT US FOR ADDITIONAL INFORMATION
For full segmentation and any questions regarding research coverage, please contact us for a complimentary demo of the full report.
